Date Time
New Study Shows Peer Pressure Could Help Teens Make Safer Choices
Peer pressure, a powerful influence in the lives of students, has rather negative connotations in society, which includes the influence of peers on juvenile delinquency and the use of alcohol or cigarettes. According to a new study, affiliated with UNIST, observing social peers making safe choices may lead some teens to make healthy decisions than they would otherwise.
Professor Dongil Chung from the Department of Biomedical Engineering at UNIST, in collaboration with neuroscientists from Virginia Tech in the United States, has examined the influential power of safe teenagers among peers in a new neuroeconomics study. Using quantitative model-based analyses, they identified behavioral and neural evidence that observing others’ safe choices increases the subjective value and selection of safe options for substance-naïve relative to substance-exposed adolescents.
Kyoto University A team of scientists led by CiRA Professor Haruhisa Inoue reports the combination of deep learning and iPS cell technology for the diagnosis of amyotrophic lateral sclerosis (ALS). For many devasting neurological diseases like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), patients are diagnosed only after becoming symptomatic. However, the evidence of memory and muscle loss is seen only after the disease has progressed to irreversible states. Researchers are therefore exploring ways to identify patients well before they become symptomatic, which could allow for wider clinical options. “If we can catch the disease at the reversible stage, we may reverse and cancel the disease.” said CiRA Prof. Haruhisa Inoue, a specialist of ALS research using iPS cells.
'Engineer the Story', run in partnership with the Ideas Foundation, helps engineers create digital stories to bring their research to life. Supported by.
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences
Vancouver, British Columbia (Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (
HaluGen ), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
Following the Company s announcement dated January 14, 2021, detailing Entheon s acquisition of HaluGen, the Company confirms that HaluGen s proprietary psychedelics genetic test kit and technology platform has completed research and development and is nearing commercial production.
Date Time
Renewed funding for national childhood arthritis research centre
The UK’s first and only research centre dedicated to testing better and more effective drug treatments for children with arthritis and related conditions has secured a further three years of funding from the charity Versus Arthritis.
The Experimental Arthritis Treatment Centre for Children (EATC4Children) is based in Liverpool at Alder Hey Children’s NHS Foundation Trust and the University of Liverpool.
Since launching in 2014 the EATC4Children has led a wide range of studies including the landmark APTITUDE trial to improve treatment for children with the severe inflammatory eye condition uveitis, and a major programme of translational research into childhood lupus.